^
Association details:
| Biomarker: | EML4-ALK fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Published date:
02/24/2021
Excerpt:
...we checked whether gilteritinib displayed antitumor activity against ALK-rearranged human NSCLC cells….Using cell viability assays, we confirmed the potent activity against EML4-ALK fusion gene (WT, v1, and v3)-positive NSCLC cells…
DOI:
https://doi.org/10.1038/s41467-021-21396-w
